Abstract
The development of a safe and effective HIV-1 vaccine is a global health priority. In 2001, the NIH established the Dale and Betty Bumpers Vaccine Research Center (VRC) to help solve key scientific and logistic challenges facing the field and to accelerate the development of HIV-1 vaccine candidates. During the past 5 years, the VRC has developed two promising vaccine platform technologies utilizing plasmid DNA vaccines and recombinant adenovirus serotype 5 (rAd5) vectors. Unlike traditional vaccine modalities that typically focus on generating antibody responses, these vaccine candidates aim to elicit HIV-1–specific cellular immune responses, which are believed to be critical for the control of HIV-1 replication. Two recent reports describe the safety and immunogenicity of these two vaccine candidates. In the first study, investigators constructed a cocktail of four plasmids expressing Gag-Pol-Nef from clade B and Env from clades A, B, and C. Fifty subjects …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
